DBV Technologies S. A. is a late stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The company's therapeutic approach relies on epicutaneous immunotherapy or EPIT which delivers biologically active compounds to the immune system through intact skin using the Viaskin patch. This mechanism targets Langerhans cells in the skin that capture antigen and migrate to lymph nodes to activate immune responses while limiting systemic exposure. The lead product candidate is Viaskin Peanut Patch designed to treat children with peanut allergy. The company is pursuing regulatory submissions for this patch in the United States and the European Union for age groups ranging from one to seven years. In addition to peanut allergy DBV Technologies S. A. has earlier stage programs for cow's milk allergy and is exploring applications in autoimmune inflammatory diseases. The overall goal is to provide safe effective and non invasive immunotherapy options for patients with high unmet medical need.

DBV Technologies S. A. generates revenue primarily through collaboration agreements licensing arrangements and milestone payments. The company has an active collaboration with Nestlé Health Science for the development and commercialization of MAG1C a diagnostic tool for cow's milk protein allergy which included an upfront payment of ten million euros and the potential to receive up to one hundred million euros in development regulatory and commercial milestones. Additionally DBV Technologies S. A. has entered into manufacturing and supply agreements with Sanofi for the exclusive production of Viaskin Peanut active pharmaceutical ingredient and with Fareva for clinical and commercial batch manufacturing. These agreements may provide revenue through product supply fees and future royalties. Until a product is approved and commercialized the company's income stream remains dependent on these partnership payments and any government or grant funding related to its research programs.

DBV Technologies S. A. operates in the competitive field of allergy immunotherapy where several established and emerging therapies exist. Key competitors include Palforzia an oral immunotherapy product approved for peanut allergy in children and Xolair an anti IgE monoclonal antibody approved for reducing allergic reactions to multiple foods. Other approaches such as oral immunotherapy sublingual immunotherapy and various monoclonal antibody programs are also in development. The company's competitive advantage lies in its proprietary Viaskin epicutaneous delivery system which offers a non invasive route of administration that aims to minimize systemic exposure and reduce the risk of severe adverse events. The technology is supported by a strong intellectual property portfolio covering the patch design the electrospray manufacturing process and methods of allergen desensitization. Additionally the company's clinical data set includes numerous Phase 2 and Phase 3 trials demonstrating statistically significant treatment effects and a favorable safety profile which differentiates it from many alternatives that carry higher rates of systemic side effects.

The company serves patients suffering from peanut allergy and related food allergies along with their caregivers and families. Target consumers include children aged one to seven years who are diagnosed with peanut allergy and their parents who seek safe treatment options. The commercial strategy also addresses allergists and pediatricians who prescribe and manage allergy therapies as well as payers and insurance providers that determine reimbursement and access. Collaboration partners such as Nestlé Health Science and Sanofi represent additional customers that engage with DBV Technologies S. A. for joint development manufacturing and supply activities. While the filing does not list individual patient names the described customer base reflects the broad set of stakeholders involved in bringing an immunotherapy product to market.